The US FDA has authorized a new drug to treat Alzheimer's disease, marking the first approval of a drug for the disease in nearly 20 years. The drug, called Aduhelm, has sparked controversy due to its high cost and mixed clinical trial results. Some experts believe the approval sets a dangerous precedent for the FDA's drug approval process.

Wellness warrior, finding balance in life

The approval of Aduhelm by the US FDA highlights the ongoing debate around high-cost drugs and their efficacy. This decision could have far-reaching implications for the future of drug approvals and healthcare economics.